Blog

Learn how TCR-like antibodies target intracellular tumor antigens through pMHC recognition. Explore their role, development, and potential in immunotherapy.

AI is transforming antibody design. Biointron explores computational methods that accelerate drug discovery and optimize therapeutic development.

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Learn how vaccines trigger antibody production, the immune mechanisms behind protection, different vaccine types, and key factors influencing efficacy and long-term immunity.

Examine how antibody discovery supports CAR-T cell engineering by improving target specificity, reducing toxicity, and advancing next-generation cancer immunotherapies.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.

scFvs combine compact design with strong binding. Biointron explores their history, therapeutic applications, and role in diagnostics and research innovation.

Discover highlights from CAS 2024, featuring advances in cancer immunotherapy, Alzheimer’s research, protein bioinformatics, and antibody engineering breakthroughs.

Discover highlights from Biointron’s Lunch & Learn with MassBio, featuring HTP antibody platforms, alpaca VHH discovery, bispecific antibodies, and ADC development.

Engineered antibody formats expanded therapeutic potential. Biointron highlights their evolution, from early innovations to modern multi-specifics transforming drug development.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.